Research conference summary from the 2014 International Task Force on ATP1A3-Related Disorders

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1212/NXG.0000000000000139</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:32071933">http://nrs.harvard.edu/urn-3:HUL.InstRepos:32071933</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>

Research conference summary from the 2014 International Task Force on ATP1A3-Related Disorders

OPEN

Hendrik Rosewich, MD
Matthew T. Sweney, MD
Suzanne DeBrosse, MD
Kevin Ess, MD, PhD
Laurie Ozuelius, PhD
Eva Andermann, MD, PhD
Fredrick Andermann, MD
Gene Andrasco
Alice Belgrade, BCBA
Allison Brashear, MD
Kathryn Swoboda, MD
Kenneth Silver, MD
Mary Zupanc, MD
Louis Viollet, MD, PhD
Masayuki Sasaki, MD
Vicky Platt
Tara Newcomb, MS
Mario Merida, MD
Joshua Magelby, PhD
Aga Lewelt, MD
Alfred L. George, Jr., MD
Aga Lewelt, MD
Joshua Magelby, PhD
Mario Merida, MD
Tara Newcomb, MS
Vicky Platt
Dominic Poncelin
Sandra Reyna, MD
Masayuki Sasaki, MD
Marcio Sotero de Menezes, MD
Kathleen Swoadner, PhD
Louis Viollet, MD, PhD
Mary Zupanc, MD
Kenneth Silver, MD
Kathryn Swoboda, MD

Correspondence to Dr. Sweney:
matthew.sweney@hsc.utah.edu

Supplemental data at Neurology.org/ng

ABSTRACT

Objective: ATP1A3-related neurologic disorders encompass a broad range of phenotypes that extend well beyond initial phenotypic criteria associated with alternating hemiplegia of childhood (AHC) and rapid-onset dystonia parkinsonism.

Methods: In 2014, the Alternating Hemiplegia of Childhood Foundation hosted a multidisciplinary workshop intended to address fundamental challenges surrounding the diagnosis and management of individuals with ATP1A3-related disorders.

Results: Workshop attendees were charged with the following: (1) to achieve consensus on expanded diagnostic criteria to facilitate the identification of additional patients, intended to supplement existing syndrome-specific diagnostic paradigms; (2) to standardize definitions for the broad range of paroxysmal manifestations associated with AHC to disseminate to families; (3) to create clinical recommendations for common recurrent issues facing families and medical care providers; (4) to review data related to the death of individuals in the Alternating Hemiplegia of Childhood Foundation database to guide future efforts in identifying at-risk subjects and potential preventative measures; and (5) to identify critical gaps where we most need to focus national and international research efforts.

Conclusions: This report summarizes recommendations of the workshop committee, highlighting the key phenotypic features to facilitate the diagnosis of possible ATP1A3 mutations, providing recommendations for genetic testing, and outlining initial acute management for common recurrent clinical conditions, including epilepsy. Neurol Genet 2017;3:e139; doi: 10.1212/NXG.0000000000000139

GLOSSARY

AHC = alternating hemiplegia of childhood; AHCF = Alternating Hemiplegia of Childhood Foundation; CAPOS = cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss; NGS = next-generation sequencing; RDP = rapid-onset dystonia parkinsonism; SUDEP = sudden unexpected death in epilepsy; WES = whole-exome sequencing.

Na+/K+ adenosine triphosphatases (sodium/potassium pumps) are P-type cation transport proteins that establish and maintain electrochemical gradients for Na+ and K+ across the plasma membrane. Mutations in the α3 catalytic subunit, encoded by ATP1A3, which in the nervous system is exclusively expressed in neurons, are associated with at least 3 distinct, yet overlapping, clinical conditions, including epilepsy.
neurologic syndromes: rapid-onset dystonia parkinsonism (RDP); alternating hemiplegia of childhood (AHC); and cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS). From the past descriptions of each entity, distinct phenotypes have emerged, demonstrating that classic AHC, classic RDP, and CAPOS syndrome constitute clinical prototypes in a continuous and still expanding phenotypic spectrum of ATP1A3-related disorders.

In June of 2014, an international consortium of experts consisting of neurologists, epileptologists, clinical geneticists, genetic counselors, physiatrists, physical therapists, psychologists, basic scientists, and foundation representatives convened in Minneapolis, MN, in conjunction with the Alternating Hemiplegia of Childhood Foundation (AHCF) International Family Meeting. A series of quarterly teleconferences performed in the year preceding the conference, including representatives from the AHCF parent advisory board and supplemented by online queries to parents via online discussion boards, were used to identify key issues and points of concern from the parent/caregiver perspective. An initial expert panel discussion and multidisciplinary workshop were followed by the selection of a task force assigned to specific key areas to further refine and revise materials over the course of the subsequent 18 months. The following article serves as a research conference summary initiated at the AHCF International Family Meeting.

Workshop attendees focused efforts on the following aims: (1) to reach consensus on an expanded diagnostic paradigm for identifying patients with an ATP1A3-related neurologic disorder to supplement existing syndrome-based diagnostic criteria; (2) to develop standardized definitions for types of episodic manifestations associated with AHC, the most complex of the ATP1A3-related neurologic phenotypes and to disseminate these among families; (3) to create initial clinical recommendations for recurrent issues facing families and medical care providers; (4) to review deaths in the AHCF database to guide future efforts in identifying at-risk subjects and potential preventative measures; and (5) to identify critical gaps where the AHC research community most needs to focus national and international efforts. The primary goal of these efforts is to promote additional reviews and discussions among the broader international community of clinicians, scientists, and family support organizations in anticipation of the robust infrastructure needed for future collaborative clinical studies and trials. In particular, natural longitudinal history data are critically needed to identify end points necessary to assess the benefit of new treatments. Our work here admittedly focused on those on the more severe end of the spectrum of ATP1A3-related disorders within developed countries. However, ATP1A3-related disorders clearly affect patients of all ages, races, and ethnicities. Continued efforts to enroll patients in registries worldwide to better understand both phenotypes and outcomes remains an important goal.

**CONSENSUS TOWARD AN EXPANDED NON–SYNDROME-BASED DIAGNOSTIC ALGORITHM FOR ATP1A3-RELATED NEUROLOGIC DISORDERS**

Numerous publications over the past 4 decades have described and subsequently refined clinical diagnostic criteria for what are now recognized to be ATP1A3-related disorders, beginning with the original description of AHC in 1971 followed by RDP in 1993 and of CAPOS in 1996. Mutations in ATP1A3 were identified as the genetic cause of RDP in 2004. It was not until 2012 that de novo mutations in ATP1A3 were found in the majority of patients with AHC. In 2014, a novel recurrent mutation in ATP1A3 was identified in patients with CAPOS. Since then, an increasing number of atypical cases with ATP1A3 mutations have been identified spanning the phenotypic spectrum between AHC, RDP, and CAPOS syndromes, creating controversy as to whether these disorders should be considered discrete syndromes or points along a broadly heterogeneous spectrum.

The identification and description of distinct neurologic syndromes has served as a critical point of reference to help clinicians identify and study rare patient populations in the absence of a clear molecular etiology. Prior to 2004 in RDP and 2012 in AHC, expert consensus-developed clinical criteria served as the primary pathway to diagnosis. More recently, important genotype-phenotype correlations relating to individual mutations have begun to emerge in ATP1A3-related neurologic disorders. We await to see whether genotype-phenotype correlations hold up over time with the accrual of new patient cohorts identified in the context of an unbiased next-generation sequencing–based approach.
Members of the task force attempted to provide a more comprehensive diagnostic approach than was afforded under previous clinical criteria. This would allow for clinicians to go beyond existing core phenotypic components in identifying ATP1A3-related disorders. As a starting point, we compiled diagnostic criteria for AHC and RDP and clinical features of CAPOS, inclusive of previously suggested supporting features based on the available literature (table 1). Next, we sought consensus on a new diagnostic paradigm that focused on major and minor neurologic symptoms or signs that broadly supported an association with mutations in ATP1A3 in the absence of a context of a specific syndrome (table 2). A brief summary of each disorder is provided below, highlighting important features both shared and distinct among the 3 syndromes. Table 3 reviews the differential diagnosis of disorders with overlapping signs and symptoms.

**Classic AHC.** Since the discovery of ATP1A3 as the causative mutation in the majority of AHC cases,⁵ ⁶ at

<table>
<thead>
<tr>
<th>Diagnostic criteria for AHC³</th>
<th>Diagnostic criteria for RDP⁴</th>
<th>Features supportive for CAPOS syndrome⁵</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Onset of paroxysmal symptoms before age 18 mo</td>
<td>1. Onset of dystonia + Parkinson disease over a few minutes to 30 d</td>
<td>1. Cerebellar ataxia</td>
</tr>
<tr>
<td>2. Repeated attacks of hemiplegia that alternate in laterality</td>
<td>2. A clear rostrocaudal gradient of involvement (face &gt; arm &gt; leg)</td>
<td>2. Areflexia</td>
</tr>
<tr>
<td>3. Episodes of quadriplegia or plegia as a separate attack or as generalization of a hemiplegic event</td>
<td>3. Prominent bulbar findings on examination</td>
<td>3. Pes cavus (not universally present)</td>
</tr>
<tr>
<td>4. Other paroxysmal symptoms including dystonic spells, oculomotor abnormalities, or autonomic symptoms either concurrent with hemiplegic attacks or independently</td>
<td>4. Absence of response to an adequate trial of L-dopa therapy (e.g., carbidopa/levodopa 25/100 mg, 1 pill 3×/d)</td>
<td>4. Optic nerve atrophy</td>
</tr>
<tr>
<td>5. Relief from symptoms upon sleep</td>
<td>5. Family history consistent with autosomal dominant inheritance but de novo mutations increasingly well documented</td>
<td>5. Sensorineural hearing loss</td>
</tr>
<tr>
<td>6. Evidence of developmental delay or neurologic findings such as choreoathetosis, dystonia, or ataxia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additional features supporting an AHC diagnosis</td>
<td>Additional features supporting an RDP diagnosis</td>
<td></td>
</tr>
<tr>
<td>a. Repeated attacks of monocular nystagmus</td>
<td>a. Minimal or no tremor at onset</td>
<td></td>
</tr>
<tr>
<td>b. Normal neuroimaging in the presence of fluctuating but persistent neurologic deficits, especially paresis or dystonia</td>
<td>b. Occasional mild limb dystonia prior to the abrupt onset of dystonia</td>
<td></td>
</tr>
<tr>
<td>c. EEG recording during typical episodes of persistent motor dysfunction fails to show electrographic seizure activity</td>
<td>c. Often associated with triggers (e.g., running, childbirth, emotional stress, or alcoholic binges) associated with the abrupt onset of symptoms</td>
<td></td>
</tr>
<tr>
<td>d. Stepwise deterioration in motor, cognitive or speech, and language functions following a prolonged episode, in the setting of ongoing paroxysmal motor signs and symptoms</td>
<td>d. Stabilization of symptoms within a month</td>
<td></td>
</tr>
<tr>
<td>e. Development of new fixed deficits with a rostrocaudal gradient of severity, resulting in persistent oromotor dystonia and dysarthria</td>
<td>e. Rare “second onsets” or abrupt worsening of symptoms later in life</td>
<td></td>
</tr>
<tr>
<td>f. Lack of family history (due to high prevalence of de novo mutations) or family history consistent with dominant inheritance</td>
<td>f. Minimal improvement overall but with limited improvement in gait</td>
<td></td>
</tr>
<tr>
<td><strong>Atypical features</strong></td>
<td><strong>Atypical features</strong></td>
<td></td>
</tr>
<tr>
<td>1. Onset over age 18 mo</td>
<td>1. Onset over age 60 y</td>
<td></td>
</tr>
<tr>
<td>2. Obvious structural abnormalities on neuroimaging studies at initial presentation</td>
<td>2. Onset of seizures after the appearance of motor symptoms</td>
<td></td>
</tr>
<tr>
<td>3. Rapid-onset ataxia with cerebellar atrophy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AHC – alternating hemiplegia of childhood; CAPOS – cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss; RDP – rapid-onset dystonia parkinsonism.

³ Adapted from references 14, 33, 38, and 39.
⁴ Adapted from references 2, 16, 20, 40, and 41.
⁵ Adapted from reference 7.
At least 34 unique mutations have been identified. AHC is characterized by recurrent episodes of paroxysmal hemiplegia, dystonia, ocular movement abnormalities (monocular nystagmus and deviation), autonomic dysfunction, as well as developmental delay. With increasing age, many patients ultimately manifest epilepsy; however, the characteristic presentation in infants includes a variety of episodic, non-epileptic tonic, dystonic, or plegic (weakness) spells that often are refractory to treatment with most therapeutic agents. The early onset and rapidly evolving clinical signs and symptoms frequently contribute to diagnostic delays. The relatively broad differential diagnosis (table 3) and the lack of a specific genetic test prior to 2012 resulted in a widely variable approach to attempts to treat paroxysmal events (often presumed to be seizures even in the absence of electrophysiologic evidence). While the most
pathognomonic events include hemiplegic or hemidystonic episodes that affect either side of the body, children also frequently have bilateral involvement, including generalized fluctuating dystonia, quadriplegia, or paresis of variable duration.

A variety of nonparoxysmal symptoms and signs become increasingly evident with age, including global developmental delays; behavioral, attentional, and executive dysfunction with variable intellectual disability; dysarthria, ataxia, chorea, dystonia, and, less frequently, pyramidal tract signs such as spasticity and hyperreflexia. To date, we have limited data on the full spectrum of the burden of acquired neurologic deficits in this population; more robust longitudinal data are needed.

Rapid-onset dystonia parkinsonism. In 2004, it was demonstrated that heterozygous mutations in the ATP1A3 gene are causative of RDP. Since then, at least 14 mutations have been identified. Clinical hallmarks of RDP include the abrupt onset of bulbar symptoms and limb dystonia with features of parkinsonism (bradykinesia and postural instability) that exhibit limited progression over weeks and little change thereafter. Dystonic symptoms typically show minimal response to l-dopa or dopaminergic agonists. The severity of acquired neurologic signs and symptoms demonstrates a rostrocaudal gradient of involvement (face > arm > leg). Disease onset has been reported between the ages of 4 and 58 years. Symptoms can be triggered by a broad range of physical, emotional, or chemical triggers. Beyond dystonia and parkinsonism, several patients with classic RDP display other symptoms including depression and anxiety/social phobia. A minority of patients develop seizures years after the disease onset. The diagnostic criteria for RDP were revised in 2007. Major and minor diagnostic criteria for RDP are summarized in table 1.

CAPOS syndrome. The constellation of CAPOS was first described as a unique clinical entity in 1996. To date, very few patients have been described with this syndrome and no information about prevalence and incidence is available. The combination of the aforementioned symptoms is characteristic of this syndrome, although these do not constitute diagnostic criteria, given the limited number of cases. A single recurrent missense mutation in ATP1A3 (c.2452G>A; Glu818Lys) has been identified in all cases to date. Of note, only 5 of 18 identified patients exhibit pes cavus, and a full spectrum of manifestations is likely broader.

The identification of an increasing number of patients with mutations in the ATP1A3 gene and phenotypic overlap of the above-mentioned diseases demonstrates that classic AHC, classic RDP, and CAPOS syndrome constitute clinical prototypes of a continuous phenotypic spectrum from ATP1A3-related disorders.

Updating the current syndrome-based diagnostic algorithm using criteria outlined in table 1, with one emphasizing the presence of the key major (pathognomonic) and minor (supporting) signs and symptoms (table 2), is intended to focus attention on the rapidly evolving spectrum of ATP1A3-related disorders for clinicians and families. Ideally, this dual approach will facilitate the earliest possible identification of the primary genetic defect in patients presenting a wider phenotypic spectrum. This will reduce the often prolonged diagnostic odyssey and facilitate prospective enrollment into clinical studies designed to help better understand the natural history of the disorder.

<table>
<thead>
<tr>
<th>Differential diagnosis of ATP1A3-related disorders</th>
<th>Molecular pathogenesis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitochondrial disorders, e.g., Leigh syndrome, MERRF, PDH deficiency, POLG1, and others (OMIM #25600, #545000, #312170, and #174763)</td>
<td>Numerous mitochondrial and nuclear genome pathogenic variants</td>
</tr>
<tr>
<td>Familial hemiplegic migraine syndromes (FH1M, OMIM #141500; FH2M, OMIM #60248; and FH3M, OMIM #609634)</td>
<td>CACNA1A, ATP1A2, and SCN1A</td>
</tr>
<tr>
<td>Dystonic cerebral palsy</td>
<td></td>
</tr>
<tr>
<td>Infantile-onset epilepsy syndromes including Dravet</td>
<td>SCN1A</td>
</tr>
<tr>
<td>Other epilepsy syndromes with Todd paralysis</td>
<td></td>
</tr>
<tr>
<td>Defects in neurotransmitter biosynthesis and metabolism, i.e., Segawa disease, aromatic amino acid decarboxylase deficiency, tyrosine hydroxylase deficiency, dihydropteridine reductase deficiency, sepiapterin reductase deficiency, 6-pyruvoyl-tetrahydropterin synthase deficiency</td>
<td>GCH1, AADC, TH, QDPR, SPR, and PTS</td>
</tr>
<tr>
<td>Other complex movement disorder phenotypes, including myoclonus dystonia</td>
<td>SCGE, KCTD17, and others</td>
</tr>
</tbody>
</table>

STANDARDIZED DEFINITIONS FOR PAROXYSMAL EVENTS IN AHC The complex and variable paroxysmal events in AHC result in challenges in defining aspects of the ATP1A3-related disorders. Currently, neither families nor clinicians use a unified set of definitions to guide them when they attempt to communicate the frequency, duration, and overall effect of types of episodes their child may be experiencing. It is often not clear to families or their clinicians how they should categorize episodes that may or may not be seizures or some other complex movement disorders. Not only does this result in an inconsistent approach among both caregivers and clinicians, it makes it more challenging for parents to determine what constitutes an emergency for which they should seek additional assistance.
urgent medical assistance. Table 4 presents a simplified nomenclature using a language more accessible for caregivers to document events in a way that might be valuable in the context of longitudinal studies or clinical trials.

**CATASTROPHIC EVENTS IN ATP1A3-RELATED DISORDERS** Over the course of the past 2 decades, 4 of 187 (2%) prospectively enrolled patients in the US/International AHCF registry with documented pathogenic mutations in ATP1A3 and clinical features consistent with AHC have died, many of them unexpectedly, with or without an apparent antecedent stressor. Three scenarios have emerged that deserve additional attention in terms of focused research, prevention strategies, and clinical management recommendations: (1) the sudden acquisition of newly acquired, nonparoxysmal severely disabling neurologic deficits, representing a substantial lasting change in the neurologic status in a previously stable patient, (2) the appearance of increasingly refractory epilepsy or bilateral dystonia and status epilepticus or status dystonicus, and (3) sudden unexpected death, with or without an obvious antecedent stressor. Admittedly, the literature regarding these scenarios, as well as potential causes and/or interventions, is essentially nonexistent. Table 5 lists age, ATP1A3 mutation, associated clinical features, perimortem circumstances, and systemic pathology data for the 4 patients with AHC.

The sudden acquisition of new and severely disabling neurologic deficits in patients with AHC, particularly dystonia, has many parallels with the acute or subacute acquisition of evolving neurologic deficits initially described in patients with RDP. However, in patients with AHC, these deficits occur in the context of an already established syndrome of paroxysmal AHC symptoms and neurodevelopmental deficits, making it initially less obvious that any episode may ultimately prove irreversible. Our understanding of the critical trigger(s) for such irreversible transformations remains unclear, since antecedent events often appear no different from hundreds of prior episodes these children may have already experienced.

Sudden unexpected death in epilepsy (SUDEP) has demanded increasing attention on the part of families and practitioners within the epilepsy community and

### Table 4 Proposed nomenclature for simplified episode description in alternating hemiplegia of childhood

<table>
<thead>
<tr>
<th>Primary episode name</th>
<th>Episode description</th>
<th>Episode subtypes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemi-body episode</td>
<td>An event involving one or more limbs on the same side of the body; episodes may or may not include abnormal eye movements or other additional features; if sides switch during an episode but the original affected side recovers, it is considered a continuation of the same episode</td>
<td>1. Hemiplegic/hemiparetic—limbs paralyzed or weak</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Dystonic—limbs or body stiff but with involuntary posturing, i.e., stuck into a particular position, head and neck often turned or extended</td>
</tr>
<tr>
<td>Full-body episode</td>
<td>Any event in which the 2 sides of the body are affected at the same time; if the right arm and left leg are affected at the same time, it is coded as ‘full-body’; if transient full-body weakness occurs when hemiparetic episodes switch sides, it would only be coded as full-body if both sides are affected for &gt;5 min</td>
<td>1. Quadriplegia or quadriparesis—all 4 limbs with loss of tone and weakness or paralysis, often associated with loss of speech and altered breathing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Tonic—all 4 limbs in sustained extension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3. Dystonic—all 4 limbs stiff but twisted into unusual postures, often associated with head turning or head and neck extension. Individual is conscious and may appear to be in significant pain or distress</td>
</tr>
<tr>
<td>Seizure-like episode</td>
<td>Any episode in which the patient seems to be unresponsive or unconscious, with or without the following features: repetitive jerking or whole body stiffening or tonic-clonic activity with rhythmic jerking movements, or whole body trembling or twitching movements</td>
<td>1. Tonic-clonic (repetitive jerking movements involving one or more limbs in focal vs whole body in generalized)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Tonic (stiffening of part of a whole body)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3. Myoclonic (lightening-like jerking movements)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4. Complex-partial (confused behavior with inability to follow commands, often in association with more complex behaviors)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5. Absence—brief episodes of unresponsiveness, often in association with brief cessation of motor activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6. Atonic—sudden loss of whole body tone, resulting in &quot;drop-attacks&quot;</td>
</tr>
</tbody>
</table>
Table 5  ATP1A3 mutation, associated clinical features, perimortem circumstances, and systemic pathology data in 4 deceased patients with AHC

<table>
<thead>
<tr>
<th>Kindred ID</th>
<th>ATP1A3 genotype</th>
<th>Additional clinical features</th>
<th>Perimortem circumstances</th>
<th>Etiology</th>
<th>Autopsy findings (systemic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>K5011 32098 F 24 D801N</td>
<td>Classic AHC phenotype from early infancy; overall, high level of social function; increase in headache and seizure frequency in the months preceding her death. Some new episode types that she described as &quot;throat closing up&quot; and &quot;painful chest spasms&quot;; carbamazepine dosage increased 1 month prior; no hemiplegic spells the month prior and no seizures the day prior to her death</td>
<td>Found dead in bed following an uneventful day in which she had no apparent indication of illness</td>
<td>Autonomic storm with neurogenic pulmonary edema?</td>
<td>Severe pulmonary edema; thickened opacified mitral valve; mild thickening of the endocardium of the left ventricle</td>
<td></td>
</tr>
<tr>
<td>K5126 32763 F 15 E815K</td>
<td>Classic AHC phenotype from early infancy; walked independently by 2 y; spoke in 2-word sentences by age 5 y; significant regression at age 10 y in the setting of adenovirus and encephalitis, after which she developed intractable complex-partial epilepsy, permanent dysarthria, dystonia, dyskinesia, and marked worsening of behavior</td>
<td>Increasing seizure frequency in the months preceding her death, resulting in refractory status epilepticus; intensive care unit course complicated by Hashimoto thyroiditis, and metabolic abnormalities, including hyperammonemia, and hypercalcemia</td>
<td>Ventilatory support voluntarily withdrawn in the setting of neuroimaging, indicating severe brain injury</td>
<td>Pneumonia and changes consistent with aspiration; dystrophic calcification of lungs and renal tubules; hepatomegaly and hepatic congestion; muscle with type IIb fiber atrophy</td>
<td></td>
</tr>
<tr>
<td>K6415 39587 F 24 P808L</td>
<td>Classic AHC symptoms presenting in infancy; frequent hemiplegic events during early childhood, which evolved to less frequent events in her teen years and emergence of some intermittent headaches; relatively high functioning, without persistent motor deficits between episodes; very social; and obesity</td>
<td>Prolonged dystonic quadriparesis off and on the day preceding the event, with &quot;chest twitching&quot;; received rectal valium before bedtime; unawaresse death in sleep, found face down, and incontinence of urine</td>
<td>Autonomic storm with neurogenic pulmonary edema</td>
<td>Generalized pulmonary edema; fatty right ventricle but normal thickness; mild dilatation of the left ventricle and thinning of the ventricular wall near the apex; and microscopic examination of heart reveals disarray and hypertrophic fibers</td>
<td></td>
</tr>
<tr>
<td>K30781 95438 M 31 G947R</td>
<td>Classic AHC symptoms presenting in infancy. History of epilepsy with grand mal seizures. One hospitalization for status epilepticus requiring induced coma 2 y prior to death, with the subsequent worsening of dysarthria, cognitive function, and impaired motor coordination. Significant initial response to flunarizine, resulting in 169 d without &quot;bilateral&quot; dystonia</td>
<td>Had been in the usual state of health, on vacation with caregivers; overdindulged in 6 snack-sized bags of &quot;Cheetos&quot;. Developed nausea and vomited once before bed; seemed okay when he went to bed a bit later than usual</td>
<td>Unawaresse death during sleep; found lying on his side with poor color, small amount of bright red blood at mouth, and gurgling after death</td>
<td>Left ventricular concentric hypertrophy without evident infarct; lung parenchyma congested with one focus of aspiration</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: AHC = alternating hemiplegia of childhood.

is the leading cause of death in the absence of status epilepticus or seizure-related trauma. A widely accepted definition for SUDEP is included in table e-1 at Neurology.org/ng. Proposed risk factors include the use of multiple anticonvulsants, poor medication compliance, uncontrolled seizures, and the presence of additional neurologic deficits, in addition to epilepsy, among others.

In light of the heightened awareness that certain molecular etiologies may predispose to an increased risk of sudden death, it should be emphasized that ATP1A3-related disorders may have a similar association, both in the presence and absence of comorbid epilepsy. ATP1A3 is expressed in human cardiac tissue, and faulty cardiac repolarization has been demonstrated in patients with AHC. Repetitive brief asystole was documented in an individual with a confirmed ATP1A3 mutation and AHC. Finally, as illustrated in table 5, 3 patients prospectively enrolled in the AHC registry who died suddenly had documented evidence of cardiac structural abnormalities, including ventricular hypertrophy, on autopsy studies. In trying to understand and prevent sudden death in ATP1A3-related neurologic disorders, it is important to create appropriate evidence-based recommendations regarding initial evaluation and long-term monitoring of cardiac status.

CRITICAL GAPS IN OUR CURRENT KNOWLEDGE OF ATP1A3-RELATED DISORDERS Children who present acutely with dystonia, encephalopathy, or ataxia in the absence of pathognomonic features of classic AHC (i.e., alternating weakness or dystonia) account for an increasing proportion of ATP1A3.
Neurology: Genetics

E815K mutation demonstrated more severe impairment in motor function, intellectual disability, and epilepsy.\(^{14,32}\) Moving forward, development of standardized multicenter databases would allow rigorous monitoring, and documentation of clinical disease evolution should help permit us to more accurately capture mutation-specific differences with prognostic implications.

In many disorders, tools such as motor function scales, timed tests, and neuropsychological tools, including age-appropriate assessments of executive and cognitive function, mood, and behavior, can be standardized for use across patient cohorts. Unfortunately, the fluctuating nature of AHC symptoms in many children makes standardized motor and cognitive function tests more challenging to use than in other more static or progressive neurologic disorders. Therefore, a focus on caregiver-reported outcomes or a measure of overall functional assessment of patients in performing daily self-care tasks may be more practical in this setting.

SUGGESTED ACUTE MANAGEMENT RECOMMENDATIONS FOR COMMONLY ENCOUNTERED ADVERSE EVENTS IN PATIENTS WITH ATP1A3-RELATED DISORDERS

During the workshop, members agreed that action plans for certain commonly encountered issues could help standardize approaches in the acute setting. These recommendations could be an invaluable tool to facilitate communication between primary caregivers and physicians when they seek urgent care for their child with an ATP1A3-related neurologic disorder. They may help streamline discussions with health care providers and minimize the risk of adverse complications. We have created initial drafts for action recommendations (see supplemental materials) to address 3 recurring clinical scenarios frequently involving affected children or adults: (1) increasingly frequent and painful dystonic crises or status dystonicus, (2) new signs or symptoms thought to be clinically consistent with epilepsy or status epilepticus, and (3) recurring behavioral crises constituting a danger to self or others.

RECOMMENDATIONS FOR MOLECULAR DIAGNOSTIC TESTING

Both AHC and RDP phenotypes can be associated with de novo mutations or dominant inheritance within families, although the vast majority of patients with AHC identified to date have de novo mutations. Because neurologic symptoms and signs associated with ATP1A3-related disorders overlap with many other neurologic syndromes, the ATP1A3 gene has been increasingly included in next-generation sequencing (NGS) panels for epilepsy, ataxia, and
dystonia/parkinsonism. Patients identified by NGS techniques account for a growing percentage of newly identified patients, whose signs and symptoms may or may not fit within the spectrum of previously described phenotypes for AHC and RDP.

Despite the important observation that mutations in the \textit{ATP1A3} gene are a frequent cause of both AHC and RDP, some individuals who meet clinical diagnostic criteria for these syndromes will not have evident pathogenic mutations in \textit{ATP1A3}. Studies continue to identify alternate molecular etiologies in patients with well-defined AHC and RDP phenotypes and for potentially valuable biomarkers that can distinguish between patients with or without pathogenic mutations in \textit{ATP1A3}. If AHC is suspected clinically and an \textit{ATP1A3} mutation cannot be identified, consideration could be given to then sequence individual genes or NGS panels that include complete coverage for genes associated with overlapping neurologic phenotypes (table 3).

A medical genetics consultation is strongly recommended before pursuing whole-exome sequencing (WES), a complex test with the potential for incidental findings that requires detailed pretest and posttest counseling. When a diagnosis of AHC or RDP is not previously suspected by the clinician, extra caution should be used in the interpretation of previously unreported or rare pathogenic mutations or variants of unknown significance (VUSs), with care taken to evaluate both the specific mutation and the symptoms of the patient for proper diagnosis along the spectrum of \textit{ATP1A3}-related disorders. Caution is warranted because VUSs are very common in panel testing and extremely common in WES. Consultation with a medical genetics professional familiar with the evaluation of a VUS and with family studies can aid in results interpretation, testing of family members, and genetic counseling.

**ATP1A3-RELATED DISORDERS AND EPILEPSY**

Approximately 50% of children with AHC also carry a diagnosis of epilepsy,\textsuperscript{32–34} although the certainty of this diagnosis can remain elusive because of similarity of epileptic and nonepileptic paroxysmal events such as dystonia, tremor, or paresis. By contrast, patients with RDP have seizures as a rare comorbidity,\textsuperscript{20} although this manifestation may be underrecognized as the number of patients with RDP is far less than AHC.

Recently, the International League Against Epilepsy revised the Operational Clinical Definition of Epilepsy to allow for the diagnosis of epilepsy following a first seizure in the context of increased recurrence risk.\textsuperscript{35} The challenge in accurately assessing the recurrence risk in adults and children with \textit{ATP1A3}-related disorders is significant and may ultimately be dependent on specific genetic mutations.

Reviews of \textit{ATP1A3}-related disorders have emphasized the potentially catastrophic course of epilepsy in patients with AHC.\textsuperscript{32} For this reason, we attempted to more precisely address seizure and epilepsy-related clinical practice issues. It was agreed that, when feasible, video-EEG characterization should be obtained when new, distinct, and stereotyped events are noted. However, the abundance and variability of paroxysmal events in AHC makes video-EEG characterization impractical for some instances. Broad input from family members, caretakers, and other medical personnel, as well as the use of personal video capabilities, may aid in more accurately characterizing the events in question.

Routine EEG may provide limited benefit early in the course of AHC evolution because classic epileptiform features are absent during most episodes.\textsuperscript{33} It is unknown whether EEG may help to better assess further risk of seizure later in the course of the disorder, when epilepsy is more typically present. Ultimately, workshop participants agreed that if clinical suspicion is high and EEG features suggestive of an underlying seizure tendency are noted, initiation of an anticonvulsant medication is warranted. If the EEG is unrevealing, then further clinical assessment and video-EEG monitoring is reasonable.

**DISCUSSION AND FUTURE DIRECTIONS.** \textit{ATP1A3}-related disorders have become increasingly recognized with the advent of more potent molecular diagnostic tools. However, substantial knowledge gaps remain in understanding how specific genetic mutations and other epigenetic phenomena might influence physiologic mechanisms to produce the variable phenotypes. There is no specific treatment for \textit{ATP1A3}-related diseases other than symptomatic, although flunarizine is widely used.\textsuperscript{36,37} There is no approved medication or device that alters the underlying deficit in the Na\textsuperscript{+}/K\textsuperscript{+} pump.

During the course of workshop proceedings, it became clear that considerable challenges remain. A critical impediment to effective clinical trial design is a lack of standardized language to capture and measure disease burden for paroxysmal symptoms in AHC. Clinical trial designs typically implemented in epilepsy are inadequate. Patients with \textit{ATP1A3}-related disorders also demonstrate variable impairments in cognition, language, mood, behavior, and gross motor and fine motor functions, and these outcomes will also be important to effectively document and assess reliably over time. Finally, development or use of caregiver and patient-reported outcome tools will likely prove a critical part of this process, especially if broader quality of life trends can be
incorporated in addition to typical event counting. This combination may in the end prove the most effective way to measure improvement in response to specific targeted interventions. Given the variable phenotype, a multifaceted approach will be needed in which outcome measures are carefully chosen to reflect the most likely benefit of any intervention.

**AUTHOR CONTRIBUTIONS**

Hendrik Rosewich: study concept and design, analysis and interpretation, study supervision, and critical revision of manuscript for important intellectual content. Matthew T. Sweeny, Suzanne DeBrosse, Kevin Ess, and Laurie Ozelius: study concept and design, analysis and interpretation, and critical revision of manuscript for important intellectual content. Alfred L. George: study concept and design, critical revision of manuscript for important intellectual content. Sharon Ciccodicola and Lynn Egan: study concept and design, analysis and interpretation, and critical revision of manuscript for important intellectual content. Allison Brashear: study concept and design, analysis and interpretation, and critical revision of manuscript for important intellectual content. Andermann, Frederick Andermann, Gene Andrasco, and Alice Belgrade: study concept and design and critical revision of manuscript for important intellectual content. Sharon Ciccodicola and Lynn Egan: study concept and design, analysis and interpretation, and critical revision of manuscript for important intellectual content. Aga Lewelt, Joshua Magelby, Mario Merida, Tara Newcomb, Vicky Platt, Dominic Ponzelin, Sandra Reyna, Masayuki Sasaki, Marcio Sotero de Menezes, Kathleen Sweadner, Louis Viollet, Mary Zupanc, and Kenneth Silver: study concept and design and critical revision of manuscript for important intellectual content. Kathryn Swoboda: study concept and design, analysis and interpretation, study supervision, and critical revision of manuscript for important intellectual content.

**STUDY FUNDING**

No targeted funding reported.

**DISCLOSURE**

Hendrik Rosewich reports no disclosures. Matthew T. Sweeny has received a speaker honorarium from LivaNova. Suzanne DeBrosse has received travel funding from the AHC Foundation; has received publishing royalties from Decision Support in Medicine LLC and Elsevier; and has received research support from NIH, Philanthropic Account for Pyruvate Dehydrogenase Complex Deficiency Research, and University Hospitals Case Medical Center. Kevin Ess has served on a scientific advisory board for Novartis Pharmaceuticals; has served on the editorial boards of the *Journal of Child Neurology and Epilepsy Currents*; receives research funding through the Alternating Hemiplegia of Childhood Foundation, NIH/National Institute of Neurological Disorders and Stroke, and the Alternating Hemiplegia Childhood Foundation; and has provided expert witness for defense (unrelated to the present study). Laurie Ozelius holds patents related to DYTI and DYTS gene tests; has received research support from NIH and the Icahn School of Medicine at Mount Sinai; and receives royalty payments from Athena Diagnostics. Eva Andermann has served on the editorial boards of the *Turkish Journal of Neurology*, *Epilepsy and Behavior*, and the *Journal of Epileptology*. Frederick Andermann has served on the editorial boards of *Brain and Development, Epilepsy and Behavior, the Journal of Epileptology*, and the *Turkish Journal of Neurology*. Gene Andrasco and Alice Belgrade report no disclosures. Allison Brashear has served on the scientific advisory boards of Ipsen and Allergan; has salary support from the National Institute of Neurological Disorders and Stroke; performs research for Allergan, Merz USA, Revance, and Ipsen; consults for Ipsen, Allergan, Revance, and WorldMeds (all grants paid directly to the Wake Forest School of Medicine); is on the Board of Directors of the American Board of Psychiatry and Neurology and of the Association of University Professors of Neurology; reviews for the *National Institute of Neurological Disorders and Stroke*; has received publishing royalties from Demos; holds a patent (pending) for Application for care management; has received research support from the National Institute of Neurological Disorders and Stroke and NIH; and has been an expert reviewer for a patient during the last year. Sharon Ciccodicola and Lynn Egan report no disclosures. Alfred L. George has served on the scientific advisory board of Amgen; has received travel funding from EpiPM Therapeutics (now called Praxis Therapeutics); has served on the editorial boards of the *Journal of Clinical Investigation, Heart Rhythm Journal, and the Journal of General Physiology*; and has received research support from Merck Xenvo Pharmaceuticals, NIH, and the Alternating Hemiplegia of Childhood Foundation. Aga Lewelt, Joshua Magelby, and Mario Merida report no disclosures. Tara Newcomb has received research support from NHICHD. Vicky Platt is an employee of Willamette Management Associates. Dominic Ponzelin, Sandra Reyna, and Masayuki Sasaki report no disclosures. Marcio Sotero de Menezes is employed by a nonprofit organization; has served on the speakers’ bureau of Cyberonics; and is an investigator for Zogenix (not related to the study in question). Kathleen Sweadner has served on the scientific advisory board of Aarhus University; has received travel funding/speaker honoraria from the Weizmann Institute, Gordon Research Conferences, the University of Lausanne, the Harvard Club of Australia, and the Royal North Shore Hospital (University of New South Wales, Australia); and has received research support from NIH. Louis Viollet reports no disclosures. Mary Zupanc has served on the scientific advisory boards of Mallinckrodt Pharma and Insys Pharma; has received travel funding/speaker honoraria from Insys Pharma, Mallinckrodt Pharma, and the Penney Epilepsy Minifellowship Program; has served on the editorial board of *Pediatric Neurology*; and has received research support from Lundbeck and Insys Pharma. Kenneth Silver has served on the scientific advisory boards of the Childhood Foundation, Marathon Pharmaceuticals, PTC Therapeutics, and Remporin Inc and has received travel funding/speaker honoraria from Munster Hospital Grand Rounds. Kathryn Swoboda has served on the scientific advisory board of AveXis; has served on the editorial board of the *Journal of Neuromuscular Disorders*; has been a consultant for the Biogen Nurtute Advisory Board; and has received research support from Ionis Pharmaceuticals, Biogen, NIH, and the University of Utah. Go to Neurology.org/ng for full disclosure forms.

**REFERENCES**

10. Sweeny MT, Newcomb TM, Swoboda KJ. The expanding spectrum of neurological phenotypes in children with ATP1A3 mutations, Alternating Hemiplegia of Childhood,


